BACKGROUND: Hip fracture is a common diagnosis in the older population, with often serious consequences. Drug treatment may be of significance for both falls and fractures. OBJECTIVE: To investigate drug treatment in older hip fracture patients, focusing on use of fall-risk-increasing and fracture-preventing drugs before and after the fracture. METHODS: This was an observational study conducted in Sahlgrenska University Hospital, Gothenburg, Sweden. The participants were 100 consecutive hip fracture patients aged > or =65 years with a median age of 86 (range 66-97) years. Seventy-three patients were female, and 87 patients had at least one strong risk factor for a fracture. Four patients died during the hospital stay, and a further 18 died within 6 months after discharge. Treatment with fall-risk-increasing and fracture-preventing drugs at admission to hospital, at discharge and 6 months after the hip fracture was measured. RESULTS: The numbers of patients treated with fall-risk-increasing drugs were 93 (93%), 96 (100%) and 73 (94%) at admission, discharge and 6-month follow-up, respectively. The median (range) number of such drugs was 3 (0-9), 4 (1-10) and 3 (0-10), respectively. A total of 17 (17%), 32 (33%) and 29 (37%) patients were treated with fracture-preventing drugs, predominantly calcium plus vitamin D, at admission, discharge and 6-month follow-up, respectively. Five patients (5%) used bisphosphonates or selective estrogen receptor modulators at admission. No additional patients had these drugs prescribed during the hospital stay. At 6-month follow-up, four more patients were treated with bisphosphonates. CONCLUSIONS: Treatment with fall-risk-increasing drugs was extensive among older hip fracture patients both before and after the fracture. The proportion of patients with fracture-preventing drugs was low at admission and increased slightly during the follow-up period. Hence, drug treatment in older hip fracture patients can be improved regarding both fall-risk-increasing drugs and fracture-preventing drugs.
BACKGROUND:Hip fracture is a common diagnosis in the older population, with often serious consequences. Drug treatment may be of significance for both falls and fractures. OBJECTIVE: To investigate drug treatment in older hip fracturepatients, focusing on use of fall-risk-increasing and fracture-preventing drugs before and after the fracture. METHODS: This was an observational study conducted in Sahlgrenska University Hospital, Gothenburg, Sweden. The participants were 100 consecutive hip fracturepatients aged > or =65 years with a median age of 86 (range 66-97) years. Seventy-three patients were female, and 87 patients had at least one strong risk factor for a fracture. Four patients died during the hospital stay, and a further 18 died within 6 months after discharge. Treatment with fall-risk-increasing and fracture-preventing drugs at admission to hospital, at discharge and 6 months after the hip fracture was measured. RESULTS: The numbers of patients treated with fall-risk-increasing drugs were 93 (93%), 96 (100%) and 73 (94%) at admission, discharge and 6-month follow-up, respectively. The median (range) number of such drugs was 3 (0-9), 4 (1-10) and 3 (0-10), respectively. A total of 17 (17%), 32 (33%) and 29 (37%) patients were treated with fracture-preventing drugs, predominantly calcium plus vitamin D, at admission, discharge and 6-month follow-up, respectively. Five patients (5%) used bisphosphonates or selective estrogen receptor modulators at admission. No additional patients had these drugs prescribed during the hospital stay. At 6-month follow-up, four more patients were treated with bisphosphonates. CONCLUSIONS: Treatment with fall-risk-increasing drugs was extensive among older hip fracturepatients both before and after the fracture. The proportion of patients with fracture-preventing drugs was low at admission and increased slightly during the follow-up period. Hence, drug treatment in older hip fracturepatients can be improved regarding both fall-risk-increasing drugs and fracture-preventing drugs.
Authors: Nathalie van der Velde; Bruno H Ch Stricker; Huib A P Pols; Tischa J M van der Cammen Journal: Br J Clin Pharmacol Date: 2006-08-30 Impact factor: 4.335
Authors: Cathleen Colón-Emeric; Maragatha Kuchibhatla; Carl Pieper; William Hawkes; Lisa Fredman; Jay Magaziner; Sheryl Zimmerman; Kenneth W Lyles Journal: Osteoporos Int Date: 2003-10-03 Impact factor: 4.507
Authors: Laura A Hart; Rod Walker; Elizabeth A Phelan; Zachary A Marcum; Naomi R M Schwartz; Paul K Crane; Eric B Larson; Shelly L Gray Journal: J Am Geriatr Soc Date: 2021-10-19 Impact factor: 5.562
Authors: Björn Belfrage; Anders Koldestam; Christina Sjöberg; Susanna M Wallerstedt Journal: Eur J Clin Pharmacol Date: 2015-01-09 Impact factor: 2.953
Authors: Jeffrey C Munson; Julie P W Bynum; John-Erik Bell; Robert Cantu; Christine McDonough; Qianfei Wang; Tor D Tosteson; Anna N A Tosteson Journal: JAMA Intern Med Date: 2016-10-01 Impact factor: 21.873
Authors: Björn Belfrage; Anders Koldestam; Christina Sjöberg; Susanna M Wallerstedt Journal: Eur J Clin Pharmacol Date: 2014-05-08 Impact factor: 2.953